Skip to main content
Clinical Trials/NCT03076034
NCT03076034Active, not recruitingNot Applicable

Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk

Beth Israel Deaconess Medical Center1 site in 1 country190 target enrollmentStarted: January 26, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
190
Locations
1
Primary Endpoint
Cortical bone tissue properties by reference point indentation

Study Overview

Brief Summary

The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA).

Detailed Description

The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as BMD. To test these hypotheses, The investigators propose two aims:

Aim 1: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with hip fractures and non-fracture controls.

The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent hip fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with hip fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

Aim 2: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with distal radius fractures to non-fracture controls.

The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent distal radius fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with distal radius fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
50 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Women with hip and wrist fractures within 2 weeks of presentation
  • •Non-fracture controls

Exclusion Criteria

  • •Unable to undergo BMD by DXA or high-resolution peripheral quantitative computed tomography (HR-pQCT)
  • •History of skeletal metastasis, primary hyperparathyroidism, Paget's disease, multiple myeloma
  • •Treatment with bisphosphonate, estrogen (within previous 3 years), teriparatide therapy, calcitonin, selective estrogen receptor modulator (SERMs,within previous 3 years)
  • •Use of glucocorticoids continuously for more than 3 months, use of anticonvulsants
  • •Prior fracture in adulthood (>age 18) for healthy controls
  • •Amendment to protocol added Arm 2, to include males >50 years with otherwise similar eligibility criteria.

Arms & Interventions

Post-menopausal women

Experimental

We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

Intervention: Reference Point Indentation (Device)

Males over 50 years

Experimental

We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

Intervention: Reference Point Indentation (Device)

Outcomes

Primary Outcomes

Cortical bone tissue properties by reference point indentation

Time Frame: Day 1

Osteoprobe measurement

Bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA)

Time Frame: Day 1

DXA at the hip and spine

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Tamara Rozental

Associate Professor, Harvard Medical School

Beth Israel Deaconess Medical Center

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Comparison of two different surgical approaches to decompress lumbar spinal nerves in patients with narrow lumbar spinal canal and instabilitySpondylodesisMusculoskeletal Diseases
ISRCTN99263604Medical University of Innsbruck154
Recruiting
Phase 4
Comparison Of Bone Thickness In Patients Treated With Special (Damon)Brackets and Normal(conventional) Brackets Using CBCT.
CTRI/2018/04/013193Dr Kranthi Kiran Tatikonda
Completed
Phase 3
Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning MethodOsteopenia
NCT00386360Warner Chilcott161
Active, not recruiting
Phase 1
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and PlaceboOsteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. Postmenopausal women with a diagnosis of osteopenia (T score between –2.5 and –1.0 based on the World Health Organization classification) may also be at risk of fracture.MedDRA version: 7.0 Level: PT Classification code 10031285
EUCTR2005-003033-41-GBProcter & Gamble Technical Centres Limited156
Active, not recruiting
Not Applicable
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and PlaceboOsteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. Postmenopausal women with a diagnosis of osteopenia (T score between –2.5 and –1.0 based on the World Health Organization classification) may also be at risk of fracture.MedDRA version: 7.0Level: PTClassification code 10031285
EUCTR2005-003033-41-DEProcter & Gamble Technical Centres Limited156